SAN FRANCISCO, May 3, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Cellmid Ltd. (ASX: CDY) (the "Company") with a twelve month target price of AUD $0.10. Ross Silver, Principal Analyst at Vista Partners stated, "We believe Cellmid represents a significant value proposition to a potential collaborator considering the breadth of the Company's midkine ("MK") patents. The size of the market its therapeutics could compete, if approved, is in excess of $15 billion." Mr. Silver continued, "Cellmid has a large portfolio of patents surrounding MK and owns 21 patent families worldwide. Cellmid plans to monetize this portfolio through two segments: Diagnostics and Therapeutics. The diagnostic programs are in a more advanced stage and are poised to face regulatory approvals first. The therapeutic programs are in pre-clinical trials; however they involve high value antibody candidates with early partner/licensing potential." Mr. Silver concluded, "Cellmid is the second Australian biotechnology company we have covered, the previous Australian biotech company we covered was named Arana and they were acquired by Cephalon (ticker: CEPH) for $318M in 2009."
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.
Disclaimer & Disclosure:
877.215.4813 or email@example.com
SOURCE Vista Partners